Dr. Pablo Campra: Difference between revisions

From Nano World Order - Wiki
VisualWikitext
Create: Dr. Pablo Campra
 
Expand Dr. Pablo Campra page with full report summary and embed uploaded PDF
 
Line 1: Line 1:
'''Dr. Pablo Campra''' is a Spanish scientist and university professor whose independent analysis of [[COVID Vaccines|COVID-19 vaccine]] vials brought him to international prominence within the alternative and independent research communities. Holding a doctorate in chemical sciences and serving as a professor at the University of Almería, Campra's academic background spans agricultural biology, environmental chemistry, and materials analysis. His transition into vaccine research was driven by a collaboration with the Spanish research group [[La Quinta Columna]], which invited him to apply rigorous analytical techniques to samples from COVID-19 vaccine vials in 2021. The findings he subsequently published — suggesting the presence of graphene-based nanomaterials — ignited significant controversy and earned him both widespread attention among independent researchers and fierce criticism from mainstream institutions.
'''Prof. Dr. Pablo Campra Madrid''' is a Spanish scientist serving as an Associate University Professor at the [[University of Almería]], Spain, holding a PhD in Chemical Sciences and a Degree in Biological Sciences. His academic background spans agricultural biology, environmental chemistry, and materials analysis. He came to international prominence within alternative and independent research communities through his controversial 2021 technical report asserting the detection of graphene-based nanomaterials — specifically reduced graphene oxide — in samples taken from [[COVID Vaccines|COVID-19 vaccine]] vials. His collaboration with the Spanish independent research group [[La Quinta Columna]] brought his findings to a wide audience, generating significant debate about the undisclosed contents of emergency-authorised vaccines and the integrity of pharmaceutical regulatory oversight.




Line 5: Line 5:
== Academic Background ==
== Academic Background ==


Campra holds a PhD in Chemical Sciences and has taught at the University of Almería in Spain, where his work has historically focused on areas including environmental biology, agricultural contamination, and the chemical analysis of biological and environmental samples. His expertise in spectroscopic and microscopic analytical methods made him one of the few Spanish academics equipped to conduct the kind of materials analysis later applied to vaccine vials.
Campra holds a PhD in Chemical Sciences and a Degree in Biological Sciences, and has taught at the University of Almería in Spain, where his work has historically focused on areas including environmental biology, agricultural contamination, and the chemical analysis of biological and environmental samples. His expertise in spectroscopic and microscopic analytical methods made him one of the few Spanish academics equipped to conduct the kind of materials analysis later applied to vaccine vials.


Although his pre-2021 academic output was largely confined to agricultural and environmental science, his technical grounding in analytical chemistry — particularly his familiarity with spectroscopic identification methods — gave his vaccine research a methodological rigour that distinguished it from purely observational claims made by other independent researchers. Campra emphasised from the outset that his findings were preliminary and required replication and further peer scrutiny, a caveat that was often omitted when his work was reported in both sympathetic and hostile media.
Although his pre-2021 academic output was largely confined to agricultural and environmental science, his technical grounding in analytical chemistry — particularly his familiarity with spectroscopic identification methods — gave his vaccine research a methodological rigour that distinguished it from purely observational claims made by other independent researchers. Campra emphasised from the outset that his findings were preliminary and required replication and further peer scrutiny, a caveat that was often omitted when his work was reported in both sympathetic and hostile media.


== Research Methodology ==
[[File:FIFO NSOM Raman.gif|thumb|right|Raman spectroscopy confocal microscope used in materials analysis]]


Campra's primary analytical tool was '''micro-Raman spectroscopy''', a non-destructive optical technique that identifies chemical compounds by measuring how molecules scatter laser light. Because every molecular structure produces a unique spectral "fingerprint," Raman spectroscopy is considered one of the most reliable methods for identifying the presence of specific carbon allotropes, including graphite, graphene oxide, and reduced graphene oxide — even at microscopic or nanoscopic concentrations.
== The Campra Report (2021) ==


In addition to Raman spectroscopy, Campra employed '''optical microscopy''' to observe the morphological characteristics of structures found in vaccine samples. The combination of spectral identification and direct visual observation was central to his methodology, allowing him not only to detect the Raman fingerprint consistent with graphene-type materials but also to photograph anomalous structures whose geometry he argued was inconsistent with known declared vaccine ingredients.
On '''November 2, 2021''', Campra published a technical report titled '''''Detection of Graphene in COVID-19 Vaccines by Micro-Raman Spectroscopy''''', electronically signed and released on ResearchGate. The report represented the results of a random screening exercise conducted on seven vaccine vials sourced from four manufacturers: '''Pfizer-BioNTech''' (four vials), '''AstraZeneca''', '''Moderna''', and '''Janssen''' (Johnson & Johnson).


Campra obtained vaccine samples from vials of products by Pfizer-BioNTech, AstraZeneca, Moderna, and Janssen (Johnson & Johnson). The samples were prepared using standard laboratory techniques and examined under controlled conditions at the University of Almería. His use of university-grade equipment lent additional credibility to the technical basis of his work, even as the conclusions he drew from the data remained heavily disputed.
The screening process examined over '''110 objects''' displaying a graphene-like appearance under optical microscopy. Of these, '''28 objects''' were selected as potentially compatible with graphene or graphene-family structures on the basis of both morphological characteristics and initial spectral data. From this subset, '''8 objects''' — designated '''Group 1''' — were found to exhibit Raman spectral signatures in unequivocal correspondence with a '''reduced graphene oxide (rGO) standard''', leading Campra to conclude that these objects could be conclusively identified as graphene oxide. Samples from both Pfizer and AstraZeneca vials contributed to the Group 1 findings.


=== Why Raman Spectroscopy Matters ===
The remaining '''20 objects''' were designated '''Group 2''' and showed Raman signals compatible with graphene or graphitic structures, though with varying degrees of spectral clarity. Group 2 was further subdivided into subgroups based on the quality and specificity of the spectral data obtained.


Raman spectroscopy is widely used in materials science, pharmaceutics, and forensic chemistry precisely because it does not require the sample to be destroyed and can identify materials at the nanoscale. In the context of [[Nanotechnology|nanomaterial]] identification, it is particularly valued for distinguishing between different forms of carbon — a critical distinction when assessing whether [[Graphene Oxide]] or related structures are present in a biological sample. Critics who dismissed Campra's findings on methodological grounds faced the challenge that the technique itself is not considered fringe: it is standard practice in materials characterisation laboratories worldwide.
A notable observation made across all samples was the presence of a '''gelatinous hydrogel residue''' remaining after the samples were dried — a substance not among the declared ingredients of any of the four vaccine products. Campra noted this residue as a point of concern warranting further characterisation.


== Key Findings ==
Crucially, [[Graphene Oxide]] was '''not declared''' as an ingredient in any of the four manufacturers' emergency use authorisations (EUAs) submitted to regulatory bodies. The presence of any graphene-family material in vaccine vials — if confirmed — would therefore represent an undisclosed component in a regulatory filing, a fact Campra highlighted as raising serious questions about pharmaceutical transparency and regulatory oversight.


In late 2021, Campra published a technical report titled '''''Detection of Graphene in Covid19 Vaccines by Micro-Raman Spectroscopy''''', circulated initially as a preprint. The report presented spectral data which Campra argued was consistent with the presence of [[Graphene Oxide]] and reduced graphene oxide in the analysed samples.
The report was electronically signed by Campra and published on ResearchGate as a preliminary scientific communication, with an explicit call for independent replication.


== Methodology ==


Campra's primary analytical technique was '''micro-Raman spectroscopy''' — a non-destructive optical method in which a focused laser beam is directed at a sample, causing the molecules present to scatter light at frequencies characteristic of their specific molecular vibrational modes. This scattered light produces a unique spectral "fingerprint" for each molecular structure, enabling precise identification of chemical compounds without requiring the sample to be destroyed or heavily processed.


Key claims within the report included:
The instrument used was a '''JASCO NRS-5100 confocal Raman microscope''', calibrated using a silicon standard at '''520 cm⁻¹''' to ensure spectral accuracy. This confocal configuration allowed Campra to obtain Raman spectra from microscopic and nanoscopic regions of the sample with high spatial resolution, reducing spectral interference from surrounding material.


* The detection of Raman spectral peaks — specifically the characteristic D band and G band signatures — consistent with graphenic carbon structures in multiple vaccine samples.
=== Spectral Markers for Graphene Structures ===
* Optical microscope observations of micron-scale and submicron structures displaying morphological characteristics — including hexagonal forms and sheet-like geometries — consistent with graphene-family materials.
* The assertion that these materials were not listed among the declared ingredients of the vaccines, raising questions about undisclosed components.
* Preliminary identification of what Campra described as "strange structures" of unknown composition alongside the graphenic material.


Campra was careful to frame his report as a preliminary scientific communication rather than a definitive proof, calling for independent replication and formal peer review. Nonetheless, the report circulated widely and was treated by many independent researchers as significant corroborating evidence for hypotheses involving [[Graphene Oxide]] as a covert additive in COVID-19 vaccine formulations.
Two primary spectral bands were used as diagnostic indicators for graphene-family materials:


His findings intersected with contemporaneous independent research being conducted by analysts including [[Mik Andersen]] (Corona2Inspect) and [[Dr. Ana Maria Mihalcea]], who were approaching similar questions through different methodological lenses. The convergence of independent findings across multiple researchers and countries was cited by proponents as strengthening the overall evidentiary picture.
* The '''G-band''' (approximately 1580–1600 cm⁻¹): arising from the in-plane stretching of carbon–carbon bonds in sp²-hybridised carbon networks, this band is characteristic of all graphitic and graphenic carbon structures.
* The '''D-band''' (approximately 1340 cm⁻¹): associated with structural defects or disorder in the graphene lattice; its presence and relative intensity compared to the G-band allows distinction between pristine graphene, graphene oxide, and reduced graphene oxide.


== Collaboration with La Quinta Columna ==
The ratio of D-band to G-band intensity (D/G ratio) is a well-established indicator of the degree of oxidation and structural disorder in graphenic carbon materials, making it a particularly useful diagnostic tool for distinguishing [[Graphene Oxide]] from other carbon allotropes.


Campra's entry into COVID-19 vaccine research was facilitated primarily through his association with '''[[La Quinta Columna]]''', a Spanish independent media and research group founded and led by [[Ricardo Delgado]]. La Quinta Columna had been among the earliest voices to publicly assert that [[Graphene Oxide]] was present in COVID-19 vaccines and was responsible for a range of observed adverse effects. Seeking scientific validation for their hypothesis, they approached Campra to conduct a formal laboratory analysis.
Campra also noted potential spectral peaks around '''1450 cm⁻¹''' in some samples — a region potentially assignable to organic compounds in combination with graphene structures. He identified similarities to spectral profiles associated with substances such as '''polyvinyl alcohol (PVA)''', '''methylacrylamide''', and '''PQT-12''' — materials that appear in experimental biomedical graphene formulations described in peer-reviewed scientific literature. The possible presence of such compounds was treated as preliminary and in need of further characterisation.


The collaboration was significant because it bridged the gap between citizen journalism and academic science. La Quinta Columna provided the platform and the public visibility; Campra provided the laboratory methodology and institutional credibility. Following the publication of his report, Campra participated in interviews and online broadcasts hosted by La Quinta Columna, where he presented and explained his findings to a general audience.
In parallel with spectroscopic analysis, Campra used '''optical microscopy''' to observe the morphological characteristics of structures found in the vaccine samples, photographing objects displaying sheet-like geometries and hexagonal forms consistent with graphene-family nanomaterials.


This collaboration was viewed with suspicion by mainstream commentators, who suggested that the relationship between Campra and an avowedly anti-vaccine media group compromised his scientific independence. Supporters countered that the methodology was what mattered, and that dismissing data because of the identity of those who funded or publicised the analysis constituted an ad hominem rather than a scientific rebuttal.
[[File:Cnt gnrarm v3.gif|thumb|right|Graphene oxide nanosheet structure as visualised by electron microscopy]]


Within the broader independent research community, Campra's work was situated alongside that of [[Corona2Inspect]] — the pseudonymous researcher later identified as [[Mik Andersen]] — whose detailed technical analyses of vaccine vial contents were published independently and reached broadly complementary conclusions. Together, these researchers formed part of an informal international network investigating the undisclosed contents of COVID-19 vaccines.
== Key Findings ==


== Institutional Response ==
A summary of the principal findings from the Campra Report:


The response from mainstream scientific and regulatory bodies was swift and largely dismissive. Spanish health authorities, aligned with the positions of the [[World Economic Forum|WHO]] and [[European Medicines Agency]], stated that COVID-19 vaccines did not contain graphene oxide and that Campra's findings were erroneous or misinterpreted. Official fact-checking organisations labelled his report as misinformation.
* '''Group 1 (8 objects)''': Raman signals in unequivocal correspondence with the reduced graphene oxide (rGO) standard used for comparison. These objects were conclusively identified by spectral fingerprinting as graphene oxide. Found in samples from Pfizer-BioNTech and AstraZeneca vials.
* '''Group 2 (20 objects)''': Raman signals compatible with graphene or graphitic carbon structures, sub-divided into groups according to spectral clarity and specificity.
* [[Graphene Oxide]] was not declared as an ingredient in any emergency use authorisation by any of the four manufacturers analysed.
* A '''gelatinous hydrogel residue''' was observed in all samples after drying, representing an additional unidentified material.
* Spectral peaks around 1450 cm⁻¹ suggested the possible co-presence of organic compounds combined with graphene structures — including substances such as PVA, methylacrylamide, and PQT-12, which appear in experimental biomedical graphene literature.
* Morphological observations under optical microscopy corroborated the spectroscopic findings, with structures displaying geometries consistent with graphene nanosheets observed across multiple samples.


Academic criticism centred on several points: the absence of formal peer review, questions about sample chain-of-custody, and alternative interpretations of the Raman spectral data — including the possibility that observed carbon signatures could originate from environmental contamination or sample preparation artefacts rather than from the vaccines themselves. Some scientists argued that the D and G band peaks Campra identified, while consistent with graphenic carbon, were insufficiently distinctive to rule out other carbonaceous contaminants.
== Significance and Reception ==


Campra responded to some of these criticisms in supplementary communications, maintaining that his methodology was sound and that the burden of proof should be on manufacturers to demonstrate transparency about all components present in their products. He also noted that calls for independent replication — which he had explicitly invited — were not being answered by institutional laboratories, a silence he and his supporters found telling.
The Campra Report was conducted as an entirely independent study, without institutional funding or formal involvement from any government body, pharmaceutical company, or regulatory agency. This independence was central to Campra's position: he argued that conflicts of interest within institutional research environments made independent analysis by researchers with no financial stake in vaccine products both necessary and appropriate.


Whether or not his findings were ultimately correct, the institutional handling of Campra's work has itself become a subject of interest to researchers studying [[Regulatory Capture]] and the suppression of independent scientific inquiry, particularly in the context of the pharmaceutical industry's relationship with regulatory agencies during the COVID-19 pandemic.
Campra explicitly called for '''independent replication''' of his findings by other researchers with no conflicts of interest — a standard scientific demand that, he noted, went largely unanswered by institutional laboratories. Critics argued that the absence of formal peer review, questions about sample chain-of-custody, and the possibility of environmental contamination or sample preparation artefacts undermined the findings. Campra addressed some of these objections in supplementary communications, maintaining that the burden of proof should rest with manufacturers to demonstrate full transparency about all materials present in their products.


Within the independent research community, the Campra Report became a foundational reference document. It was cited alongside complementary work by [[Mik Andersen]] (the researcher behind [[Corona2Inspect]]), whose detailed technical analyses of vaccine vial contents reached broadly consistent conclusions through parallel methodological approaches. [[Dr. Ana Maria Mihalcea]]'s live blood analysis research, which documented anomalous self-assembling structures in the blood of vaccinated individuals, was also frequently cross-referenced with Campra's findings as part of a broader convergent evidentiary picture.


[[Ricardo Delgado]] and [[La Quinta Columna]] — the Spanish independent research collective that originally facilitated Campra's analysis — continued to publish and publicise the findings widely, situating them within a larger framework linking [[Graphene Oxide]] to observed adverse effects, [[Self-Assembling Nanostructures]] in biological samples, and hypotheses about the covert introduction of nanomaterial components via mass vaccination programmes.


== Significance Within Independent Research ==
For researchers investigating [[Graphene in Vaccines]], the [[Intra-Body Nano Network]], and related topics, the Campra Report remains one of the most technically specific and methodologically grounded documents in the public domain, regardless of the ongoing institutional controversy surrounding its conclusions. Whether read as a preliminary scientific communication awaiting replication or as a suppressed finding of major public health significance, its place in the independent research literature on COVID-19 vaccine contents is well established.


For researchers studying [[Self-Assembling Nanostructures]], the [[Intra-Body Nano Network]], and the broader [[Transhumanist Agenda]], Campra's work occupies an important position in the evidentiary landscape. If the presence of undisclosed graphene-based nanomaterials in vaccine vials were confirmed, it would provide a potential physical substrate for several hypotheses advanced within this research community:
[[File:Bilbao University of Deusto 001.jpg|thumb|right|University of Almería, Spain, where Dr. Pablo Campra conducted his analysis]]


* [[Graphene Oxide]] and reduced graphene oxide are known to be highly biocompatible, electrically conductive, and capable of interacting with biological tissues — properties that would be relevant to the construction of in-body sensor or communication networks.
== Disclaimer ==
* [[Self-Assembling Nanostructures]] observed by researchers including [[Dr. Ana Maria Mihalcea]] in vaccinated blood samples have been hypothesised to incorporate graphenic scaffolding or carbon-based nanomaterial components.
* The [[Intra-Body Nano Network]] hypothesis, developed in detail by [[Mik Andersen]] and others, posits that nano-scale components introduced via injection could self-organise into functional networks capable of receiving and transmitting data — a concept that would require conductive nanomaterials of precisely the type Campra claimed to have identified.
* Within the framework of the [[Transhumanist Agenda]], undisclosed nanomaterials in vaccines are interpreted by some researchers as a covert step toward the involuntary integration of human biology with [[Brain-Computer Interface|brain-computer interface]] infrastructure or biosurveillance systems.


Campra's work is frequently cited by researchers including [[Dr. Ana Maria Mihalcea]], independent journalists, and contributors to platforms tracking nanotechnology-related developments in COVID-19 vaccine products. His report remains one of the most technically detailed public-domain documents in this space, regardless of the ongoing controversy about its conclusions.
Campra explicitly stated in his report that the characterisation of graphene-family materials applies '''only to the specific samples analysed''' and cannot be generalised to entire vaccine batches or the broader vaccine supply without substantially broader sampling. He further noted that he bears no responsibility for interpretations, conclusions, or claims made by third parties beyond the content of his electronically signed document. This disclaimer was frequently overlooked in both sympathetic and hostile secondary reporting on his work.


== Publications and Reports ==
== Publications and Reports ==


* ''Detection of Graphene in Covid19 Vaccines by Micro-Raman Spectroscopy'' (2021) — preliminary technical report; widely circulated as preprint
* ''Detection of Graphene in COVID-19 Vaccines by Micro-Raman Spectroscopy'' (November 2, 2021) — electronically signed preliminary technical report; published on ResearchGate;
* Supplementary Raman spectroscopy reports addressing responses from critics (2021–2022)
* Supplementary Raman spectroscopy reports addressing responses from critics (2021–2022)
* Various interviews and presentations conducted with [[La Quinta Columna]] and affiliated platforms
* Various interviews and presentations conducted with [[La Quinta Columna]] and affiliated platforms
Line 81: Line 85:
* [[Graphene Oxide]]
* [[Graphene Oxide]]
* [[Graphene]]
* [[Graphene]]
* [[Graphene in Vaccines]]
* [[COVID Vaccines]]
* [[COVID Vaccines]]
* [[Self-Assembling Nanostructures]]
* [[Self-Assembling Nanostructures]]
Line 87: Line 92:
* [[Corona2Inspect]]
* [[Corona2Inspect]]
* [[La Quinta Columna]]
* [[La Quinta Columna]]
* [[Ricardo Delgado]]
* [[Mik Andersen]]
* [[Mik Andersen]]
* [[Nanotechnology]]
* [[Nanotechnology]]
Line 92: Line 98:
* [[Brain-Computer Interface]]
* [[Brain-Computer Interface]]
* [[Biosurveillance]]
* [[Biosurveillance]]
* [[Regulatory Capture]]


[[Category:People]]
[[Category:People]]
[[Category:Nanotechnology]]
[[Category:Nanotechnology]]
[[Category:Transhumanist Agenda]]
[[Category:COVID-19]]
[[Category:COVID-19]]
[[Category:Mind Control]]
[[Category:Mind Control]]
[[Category:Graphene]]

Latest revision as of 04:57, 31 July 2026

Prof. Dr. Pablo Campra Madrid is a Spanish scientist serving as an Associate University Professor at the University of Almería, Spain, holding a PhD in Chemical Sciences and a Degree in Biological Sciences. His academic background spans agricultural biology, environmental chemistry, and materials analysis. He came to international prominence within alternative and independent research communities through his controversial 2021 technical report asserting the detection of graphene-based nanomaterials — specifically reduced graphene oxide — in samples taken from COVID-19 vaccine vials. His collaboration with the Spanish independent research group La Quinta Columna brought his findings to a wide audience, generating significant debate about the undisclosed contents of emergency-authorised vaccines and the integrity of pharmaceutical regulatory oversight.


Academic Background

Campra holds a PhD in Chemical Sciences and a Degree in Biological Sciences, and has taught at the University of Almería in Spain, where his work has historically focused on areas including environmental biology, agricultural contamination, and the chemical analysis of biological and environmental samples. His expertise in spectroscopic and microscopic analytical methods made him one of the few Spanish academics equipped to conduct the kind of materials analysis later applied to vaccine vials.

Although his pre-2021 academic output was largely confined to agricultural and environmental science, his technical grounding in analytical chemistry — particularly his familiarity with spectroscopic identification methods — gave his vaccine research a methodological rigour that distinguished it from purely observational claims made by other independent researchers. Campra emphasised from the outset that his findings were preliminary and required replication and further peer scrutiny, a caveat that was often omitted when his work was reported in both sympathetic and hostile media.

Raman spectroscopy confocal microscope used in materials analysis

The Campra Report (2021)

On November 2, 2021, Campra published a technical report titled Detection of Graphene in COVID-19 Vaccines by Micro-Raman Spectroscopy, electronically signed and released on ResearchGate. The report represented the results of a random screening exercise conducted on seven vaccine vials sourced from four manufacturers: Pfizer-BioNTech (four vials), AstraZeneca, Moderna, and Janssen (Johnson & Johnson).

The screening process examined over 110 objects displaying a graphene-like appearance under optical microscopy. Of these, 28 objects were selected as potentially compatible with graphene or graphene-family structures on the basis of both morphological characteristics and initial spectral data. From this subset, 8 objects — designated Group 1 — were found to exhibit Raman spectral signatures in unequivocal correspondence with a reduced graphene oxide (rGO) standard, leading Campra to conclude that these objects could be conclusively identified as graphene oxide. Samples from both Pfizer and AstraZeneca vials contributed to the Group 1 findings.

The remaining 20 objects were designated Group 2 and showed Raman signals compatible with graphene or graphitic structures, though with varying degrees of spectral clarity. Group 2 was further subdivided into subgroups based on the quality and specificity of the spectral data obtained.

A notable observation made across all samples was the presence of a gelatinous hydrogel residue remaining after the samples were dried — a substance not among the declared ingredients of any of the four vaccine products. Campra noted this residue as a point of concern warranting further characterisation.

Crucially, Graphene Oxide was not declared as an ingredient in any of the four manufacturers' emergency use authorisations (EUAs) submitted to regulatory bodies. The presence of any graphene-family material in vaccine vials — if confirmed — would therefore represent an undisclosed component in a regulatory filing, a fact Campra highlighted as raising serious questions about pharmaceutical transparency and regulatory oversight.

The report was electronically signed by Campra and published on ResearchGate as a preliminary scientific communication, with an explicit call for independent replication.

Methodology

Campra's primary analytical technique was micro-Raman spectroscopy — a non-destructive optical method in which a focused laser beam is directed at a sample, causing the molecules present to scatter light at frequencies characteristic of their specific molecular vibrational modes. This scattered light produces a unique spectral "fingerprint" for each molecular structure, enabling precise identification of chemical compounds without requiring the sample to be destroyed or heavily processed.

The instrument used was a JASCO NRS-5100 confocal Raman microscope, calibrated using a silicon standard at 520 cm⁻¹ to ensure spectral accuracy. This confocal configuration allowed Campra to obtain Raman spectra from microscopic and nanoscopic regions of the sample with high spatial resolution, reducing spectral interference from surrounding material.

Spectral Markers for Graphene Structures

Two primary spectral bands were used as diagnostic indicators for graphene-family materials:

  • The G-band (approximately 1580–1600 cm⁻¹): arising from the in-plane stretching of carbon–carbon bonds in sp²-hybridised carbon networks, this band is characteristic of all graphitic and graphenic carbon structures.
  • The D-band (approximately 1340 cm⁻¹): associated with structural defects or disorder in the graphene lattice; its presence and relative intensity compared to the G-band allows distinction between pristine graphene, graphene oxide, and reduced graphene oxide.

The ratio of D-band to G-band intensity (D/G ratio) is a well-established indicator of the degree of oxidation and structural disorder in graphenic carbon materials, making it a particularly useful diagnostic tool for distinguishing Graphene Oxide from other carbon allotropes.

Campra also noted potential spectral peaks around 1450 cm⁻¹ in some samples — a region potentially assignable to organic compounds in combination with graphene structures. He identified similarities to spectral profiles associated with substances such as polyvinyl alcohol (PVA), methylacrylamide, and PQT-12 — materials that appear in experimental biomedical graphene formulations described in peer-reviewed scientific literature. The possible presence of such compounds was treated as preliminary and in need of further characterisation.

In parallel with spectroscopic analysis, Campra used optical microscopy to observe the morphological characteristics of structures found in the vaccine samples, photographing objects displaying sheet-like geometries and hexagonal forms consistent with graphene-family nanomaterials.

Graphene oxide nanosheet structure as visualised by electron microscopy

Key Findings

A summary of the principal findings from the Campra Report:

  • Group 1 (8 objects): Raman signals in unequivocal correspondence with the reduced graphene oxide (rGO) standard used for comparison. These objects were conclusively identified by spectral fingerprinting as graphene oxide. Found in samples from Pfizer-BioNTech and AstraZeneca vials.
  • Group 2 (20 objects): Raman signals compatible with graphene or graphitic carbon structures, sub-divided into groups according to spectral clarity and specificity.
  • Graphene Oxide was not declared as an ingredient in any emergency use authorisation by any of the four manufacturers analysed.
  • A gelatinous hydrogel residue was observed in all samples after drying, representing an additional unidentified material.
  • Spectral peaks around 1450 cm⁻¹ suggested the possible co-presence of organic compounds combined with graphene structures — including substances such as PVA, methylacrylamide, and PQT-12, which appear in experimental biomedical graphene literature.
  • Morphological observations under optical microscopy corroborated the spectroscopic findings, with structures displaying geometries consistent with graphene nanosheets observed across multiple samples.

Significance and Reception

The Campra Report was conducted as an entirely independent study, without institutional funding or formal involvement from any government body, pharmaceutical company, or regulatory agency. This independence was central to Campra's position: he argued that conflicts of interest within institutional research environments made independent analysis by researchers with no financial stake in vaccine products both necessary and appropriate.

Campra explicitly called for independent replication of his findings by other researchers with no conflicts of interest — a standard scientific demand that, he noted, went largely unanswered by institutional laboratories. Critics argued that the absence of formal peer review, questions about sample chain-of-custody, and the possibility of environmental contamination or sample preparation artefacts undermined the findings. Campra addressed some of these objections in supplementary communications, maintaining that the burden of proof should rest with manufacturers to demonstrate full transparency about all materials present in their products.

Within the independent research community, the Campra Report became a foundational reference document. It was cited alongside complementary work by Mik Andersen (the researcher behind Corona2Inspect), whose detailed technical analyses of vaccine vial contents reached broadly consistent conclusions through parallel methodological approaches. Dr. Ana Maria Mihalcea's live blood analysis research, which documented anomalous self-assembling structures in the blood of vaccinated individuals, was also frequently cross-referenced with Campra's findings as part of a broader convergent evidentiary picture.

Ricardo Delgado and La Quinta Columna — the Spanish independent research collective that originally facilitated Campra's analysis — continued to publish and publicise the findings widely, situating them within a larger framework linking Graphene Oxide to observed adverse effects, Self-Assembling Nanostructures in biological samples, and hypotheses about the covert introduction of nanomaterial components via mass vaccination programmes.

For researchers investigating Graphene in Vaccines, the Intra-Body Nano Network, and related topics, the Campra Report remains one of the most technically specific and methodologically grounded documents in the public domain, regardless of the ongoing institutional controversy surrounding its conclusions. Whether read as a preliminary scientific communication awaiting replication or as a suppressed finding of major public health significance, its place in the independent research literature on COVID-19 vaccine contents is well established.

University of Almería, Spain, where Dr. Pablo Campra conducted his analysis

Disclaimer

Campra explicitly stated in his report that the characterisation of graphene-family materials applies only to the specific samples analysed and cannot be generalised to entire vaccine batches or the broader vaccine supply without substantially broader sampling. He further noted that he bears no responsibility for interpretations, conclusions, or claims made by third parties beyond the content of his electronically signed document. This disclaimer was frequently overlooked in both sympathetic and hostile secondary reporting on his work.

Publications and Reports

  • Detection of Graphene in COVID-19 Vaccines by Micro-Raman Spectroscopy (November 2, 2021) — electronically signed preliminary technical report; published on ResearchGate;
  • Supplementary Raman spectroscopy reports addressing responses from critics (2021–2022)
  • Various interviews and presentations conducted with La Quinta Columna and affiliated platforms

See Also

Retrieved from "https://nanoworldorder.com/wiki/index.php?title=Dr._Pablo_Campra&oldid=2057"